canrenoic acid has been researched along with eplerenone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| MacDonald, TM; Parthasarathy, HK | 1 |
| Drogies, T; Felix, SB; Ghaleh, B; Krieg, T; Schmidt, K; Tissier, R | 1 |
| Beygui, F; Ecollan, P; Flather, M; Hamm, CW; Lopez De Sa, E; Machecourt, J; Montalescot, G; Pitt, B; Van Belle, E; Verheugt, FWA; Vicaut, E; Zannad, F | 1 |
2 review(s) available for canrenoic acid and eplerenone
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonists.
Topics: Animals; Canrenoic Acid; Cardiovascular Diseases; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2007 |
Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.
Topics: Aged; Canrenoic Acid; Eplerenone; Equivalence Trials as Topic; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Risk Factors; Spironolactone; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2018 |
1 other study(ies) available for canrenoic acid and eplerenone
| Article | Year |
|---|---|
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion.
Topics: Animals; Canrenoic Acid; Eplerenone; Ischemic Preconditioning, Myocardial; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphorylation; Phosphotransferases; Rabbits; Rats; Rats, Wistar; Spironolactone | 2010 |